Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yann-Alexandre Vano

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Expert Review of Anticancer Therapy|March 20, 2014
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agentsYann-Alexandre Vano, Eric Tartour, Laure S Fournier, et al.
The Lancet. Oncology|June 30, 2022
Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinomaYann-Alexandre Vano, Réza Elaidi, Letuan Phan, et al.
Bulletin Du Cancer|July 5, 2020
[Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer]Audrey Simonaggio, Nicolas Epaillard, Reza Elaidi, et al.
Bulletin Du Cancer|June 27, 2022
Future treatment options in metastatic clear cell renal cell carcinomaAudrey Simonaggio, Marie Auvray-Kuentz, Adrien Rochand, et al.
The Lancet. Oncology|June 30, 2022
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' replyYann-Alexandre Vano, Réza Elaidi, Letuan Phan, et al.
Bulletin Du Cancer|July 5, 2020
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIOConstance Thibault, Reza Elaidi, Yann-Alexandre Vano, et al.
Plos One|April 7, 2018
Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patientsYann-Alexandre Vano, Stéphane Oudard, Marie-Agnès By, et al.
Future Oncology (London, England)|January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a reviewCedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Bulletin Du Cancer|April 11, 2017
[French national survey on incoming phone calls in oncology departments]Florence Joly, Aline Guillot, Yann-Alexandre Vano, et al.
Bulletin Du Cancer|July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancerNicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Expert Review of Anticancer Therapy|March 20, 2014
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agentsYann-Alexandre Vano, Eric Tartour, Laure S Fournier, et al.
The Lancet. Oncology|June 30, 2022
Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinomaYann-Alexandre Vano, Réza Elaidi, Letuan Phan, et al.
Bulletin Du Cancer|July 5, 2020
[Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer]Audrey Simonaggio, Nicolas Epaillard, Reza Elaidi, et al.
Bulletin Du Cancer|June 27, 2022
Future treatment options in metastatic clear cell renal cell carcinomaAudrey Simonaggio, Marie Auvray-Kuentz, Adrien Rochand, et al.
The Lancet. Oncology|June 30, 2022
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' replyYann-Alexandre Vano, Réza Elaidi, Letuan Phan, et al.
Bulletin Du Cancer|July 5, 2020
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIOConstance Thibault, Reza Elaidi, Yann-Alexandre Vano, et al.
Plos One|April 7, 2018
Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patientsYann-Alexandre Vano, Stéphane Oudard, Marie-Agnès By, et al.
Future Oncology (London, England)|January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a reviewCedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Bulletin Du Cancer|April 11, 2017
[French national survey on incoming phone calls in oncology departments]Florence Joly, Aline Guillot, Yann-Alexandre Vano, et al.
Bulletin Du Cancer|July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancerNicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Pageof 5